The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial
Simon Rule, Paul Smith, Peter WM Johnson, Simon Bolam, George Follows, Joanne Gambell, Peter Hillmen, Andrew Jack, Stephen Johnson, Amy A Kirkwood, Anton Kruger, Christopher Pocock, John F Seymour, Milena Toncheva, Jan Walewski, David Linch
HAEMATOLOGICA | FERRATA STORTI FOUNDATION | Published : 2016
Mantle cell lymphoma is an incurable and generally aggressive lymphoma that is more common in elderly patients. Whilst a number of different chemotherapeutic regimens are active in this disease, there is no established gold standard therapy. Rituximab has been used widely to good effect in B-cell malignancies but there is no evidence that it improves outcomes when added to chemotherapy in this disease. We performed a randomized, open-label, multicenter study looking at the addition of rituximab to the standard chemotherapy regimen of fludarabine and cyclophosphamide in patients with newly diagnosed mantle cell lymphoma. A total of 370 patients were randomized. With a median follow up of six ..View full abstract
Awarded by CR UK
Awarded by Cancer Research UK
Awarded by National Institute for Health Research
This trial was funded by CR UK (CRUK/06/013) and conducted by the CR UK and UCL Cancer Trials Centre.